Osilodrostat
Anticorticosteroids
Sold as Isturisa
- Drug class
- Anticorticosteroids
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 7
Overview
Osilodrostat is an active pharmaceutical ingredient in the Anticorticosteroids group (H02CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | May 22, 2026 |
| EU European Union | EMA | 1 | December 12, 2024 |
| CA Canada | Health Canada | 3 | April 17, 2026 |
GBUnited Kingdom· MHRA
3 products
Uses
Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.
How to take
EUEuropean Union· EMA
1 product
Uses
Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.
How to take
CACanada· Health Canada
3 products
3 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Osilodrostat. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 396. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB152660030 · revised May 22, 2026
- [2]European Medicines Agency · EMEA/H/C/004821 · revised December 12, 2024
- [3]Health Canada (DPD) · 02558912 · revised January 19, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.